UBS Group
CELU icon

UBS Group’s Celularity CELU Stock Holding History

UBS Group’s Portfolio CELU Stock Details CELU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Sell
1,680
-2,849
-63% -$2.73K ﹤0.01% 9660
2026
Q1 		$6.02K Buy
4,529
+1,186
+35% +$1.5K ﹤0.01% 8724
2025
Q4 		$3.71K Buy
3,343
+2,128
+175% +$3.82K ﹤0.01% 8965
2025
Q3 		$2.52K Hold
1,215
– – ﹤0.01% 9160
2025
Q2 		$2.38K Hold
1,215
– – ﹤0.01% 9480
2025
Q1 		$2.1K Hold
1,215
– – ﹤0.01% 9391
2024
Q4 		$2.53K Sell
1,215
-4,802
-80% -$11.5K ﹤0.01% 9034
2024
Q3 		$17.9K Buy
6,017
+4,802
+395% +$14.1K ﹤0.01% 7432
2024
Q2 		$3.8K Sell
1,215
-2
-0.2% -$7 ﹤0.01% 8171
2024
Q1 		$6.37K Hold
1,217
– – ﹤0.01% 7464
2023
Q4 		$3.01K Sell
1,217
-39
-3% -$85 ﹤0.01% 8023
2023
Q3 		$2.79K Sell
1,256
-385
-23% -$1.38K ﹤0.01% 7645
2023
Q2 		$8.75K Sell
1,641
-1,641
-50% -$10.5K ﹤0.01% 7215
2023
Q1 		$20.3K Buy
3,282
+1,811
+123% +$14.6K ﹤0.01% 7065
2022
Q4 		$19K Buy
1,471
+780
+113% +$14.4K ﹤0.01% 7704
2022
Q3 		$16K Sell
691
-339
-33% -$10.3K ﹤0.01% 7674
2022
Q2 		$36K Buy
1,030
+659
+178% +$53.5K ﹤0.01% 6182
2022
Q1 		$32K Sell
371
-306
-45% -$18.3K ﹤0.01% 6916
2021
Q4 		$35K Buy
677
+387
+133% +$24.7K ﹤0.01% 7223
2021
Q3 		$21K Buy
290
+203
+233% +$16.4K ﹤0.01% 7104
2021
Q2 		$9K Sell
87
-245
-74% -$24.8K ﹤0.01% 8127
2021
Q1 		$33K Buy
332
+228
+219% +$23.4K ﹤0.01% 6921
2020
Q4 		$11K Buy
104
+94
+940% +$9.99K ﹤0.01% 7398
2020
Q3 		$1K Sell
10
-1
-9% -$104 ﹤0.01% 7764
2020
Q2 		$1K Sell
11
-3
-21% -$298 ﹤0.01% 7743
2020
Q1 		$1K Sell
14
-1,236
-99% -$122K ﹤0.01% 7740
2019
Q4 		$124K Buy
+1,250
New +$124K ﹤0.01% 5892

Other funds holding CELU

CVSC
C.V. Starr & Co New York $187M AUM 26.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BFO
Biltmore Family Office Charlotte, North Carolina $761M AUM 31.91% 1-Year Est. Return

UBS Group's CELU Position: Q2 2026 in Review

UBS Group reduced its Celularity (CELU) stake by 63% in Q2 2026, selling an estimated $2.73K and leaving 1,680 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #9660.

UBS Group first reported a position in CELU in Q4 2019 and has held it in 27 quarters since. The position peaked at $124K in Q4 2019. 39 funds tracked by Wall St. Rank hold CELU as of Q2 2026.

  • UBS Group held 1,680 shares of Celularity worth $1K as of Q2 2026.
  • UBS Group sold 2,849 Celularity shares in Q2 2026, an estimated $2.73K.
  • Celularity made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #9660 holding.
  • UBS Group first reported a position in Celularity in Q4 2019 and has held it in 27 quarters since.
  • UBS Group's Celularity position peaked at $124K in Q4 2019.
  • 39 funds tracked by Wall St. Rank held Celularity as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.